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6Abstract 
Plants have been used in treatment and prevention of diseases for thousands of years. In 
modern medicine there is a trend towards isolation and identification of bioactive molecules, 
whereas plant preparations continue to be used in traditional medicinal systems. However, 
combinations of drugs are usually administered in treatment of complex diseases like cancer 
and HIV, in order to target multiple deregulated cellular pathways simultaneously.  
Khat (Catha edulis Forsk.) has been cultivated for centuries primarily due to its use as a 
natural stimulant. The stimulating potential of khat is mainly caused by its content of 
cathinone, an alkaloid with structure and pharmacological profile similar to amphetamine. 
Cathinone is a labile precursor for the less bioactive derivatives cathine and norephedrine. 
An organic extract of khat was previously reported to induce programmed cell death in acute 
myeloid leukemia (AML) cell lines, while being less toxic to normal peripheral blood 
mononuclear cells (PBMCs). In this study, cellular and molecular effects of an extract of 
khat were further elucidated in AML cell lines and compared with the cancer therapeutics 
camptothecin. Early effects of khat and the khat amphetamines on intracellular signaling 
responses in normal peripheral leukocytes were investigated, in addition to cytotoxic effects. 
The khat extract was fractionated and analysed for cytotoxicity in AML cell lines, and the 
fractions analysed by mass spectrometry.  
The khat extract was shown to induce cell death in a subset of genetically diverse AML cell 
lines, indicating involvement of specific mechanisms. In contrast to camptothecin, khat 
caused structural damage to mitochondria and mediated impaired mitochondrial respiration. 
In addition, khat was observed to induce formation of autophagosomes, indicating activation 
of autophagy. The survival protein Bcl-2 protected against camptothecin, and partial 
protection was obtained against khat-induced cell death. Procaspase-8 of the receptor-
mediated cell death pathway was activated by khat, while levels of the death antagonists 
Mcl-1 and c-FLIPL were reduced. The stress sensor and tumour suppressor protein p53 was 
induced and modulated in khat-mediated death, but not by sub-lethal dilutions of the khat 
extract or in khat-resistant cells. Experiments using p53 knock-down and knock-out cells 
demonstrated that khat-mediated cell death was independent of p53. The p53 protein was 
7suggested to primarily act as a stress sensor in AML cells that were susceptible to khat-
induced cell death.  
Fractionation of the khat extract and bio-guided screening in AML cell lines resulted in 
identification of three separate cytotoxic fractions. The khat fractions were analysed by mass 
spectrometry, which led to the partial characterization of a phenylpropanoid glycoside 
suggested to represent the major cytotoxic constituent in the khat extract. In contrast to khat, 
the khat amphetamines were observed to be relatively non-toxic to AML cell lines. Khat and 
the khat amphetamines were shown to mediate early and generally opposite effects on 
signaling mediators in normal immune cells. Whereas khat activated stress sensors, like p38 
and p53, and demonstrated cytotoxic effects, the khat amphetamines attenuated activating 
modifications of several signaling proteins, including p53, and appeared to have a 
stimulating effect on lymphocyte proliferation. 
8Sammendrag 
Planter har blitt brukt i behandling og forebygging av sykdom i tusener av år. I moderne 
medisin er det vanlig å isolere og identifisere bioaktive substanser, mens plantepreparater 
fortsatt blir brukt i tradisjonelle medisinske systemer. Kombinasjoner av ulike typer medisin 
er likevel vanlig ved behandling av sykdommer som kreft og HIV, med den hensikt å ramme 
flere av de deregulerte cellulære signalveiene som forårsaker sykdom.   
Khat (Catha edulis Forsk.) har blitt dyrket i århundrer, først og fremst for å bli benyttet som 
en naturlig stimulant. Den stimulerende effekten skyldes primært khat plantens innhold av 
katinon, et alkaloid som har lignende struktur og farmakologisk profil som amfetamin. 
Katinon er en labil forbindelse som blir omdannet til de mindre stimulerende derivatene 
katin og norefedrin. Et organisk ekstrakt av khat ble tidligere vist å aktivere programmert 
celledød i akutt myelogen leukemi (AML) cellelinjer, mens det var mindre toksisk for 
normale perifere blod mononukleære celler (PBMC). I denne studien ble de cellulære og 
molekylære effektene av et khat ekstrakt videre undersøkt i AML cellelinjer, og 
sammenlignet med kreftmedisinen camptothecin. Tidlige effekter av khat og khat 
amfetaminene på intracellulære signaleringsproteiner ble undersøkt i normale leukocytter, i 
tillegg til cytotoksiske effekter. Khat ekstraktet ble fraksjonert og undersøkt for cytotoksiske 
effekter i AML cellelinjer, og fraksjonene ble analysert med massespektrometri.   
Khat ekstraktet ble vist å indusere celledød i et utvalg av genetisk ulike AML cellelinjer, noe 
som indikerte aktivering av spesifikke mekanismer. I motsetning til camptothecin førte khat 
behandling til strukturell skade i mitokondriene, noe som hemmet den mitokondrielle 
respirasjonen. Videre ble det observert at khat induserte dannelse av autofagosomer, noe som 
indikerte aktivering av autofagi. Overlevelsesproteinet Bcl-2 beskyttet mot camptothecin, 
men ga bare delvis beskyttelse mot khat-indusert celledød. Procaspase-8, som er del av den 
reseptormedierte celledødsveien, ble aktivert av khat, mens nivåene av dødsantagonistene 
Mcl-1 og c-FLIPL ble redusert. Stress sensor og tumor suppressor proteinet p53 ble indusert 
og modulert i khat-mediert død, med ikke av ikke-dødelige khat doser eller i khat-resistente 
celler. Eksperimenter med p53 knock-out og knock-down celler viste at p53 ikke var 
nødvendig i khat-mediert celledød. p53 proteinet ble foreslått å fungere primært som en 
stress sensor i AML celler som var sensitive for khat.  
9Fraksjonering av khat ekstraktet og testing av fraksjonene for toksisitet i AML cellelinjer, 
resulterte i identifisering av tre separate cytotoksiske fraksjoner. Khat fraksjonene ble 
analysert med massespektrometri, og et fenylpropanoid glykosid ble delvis karakterisert og 
foreslått å være den mest toksiske komponenten i khat ekstraktet. In motsetning til khat ble 
khat amfetaminene vist å være relativt ikke-toksiske i khat-sensitive AML celler. Khat og 
khat amfetaminene ble vist å gi hurtige og generelt motsatte effekter på ulike signalerings-
proteiner i normale immun celler. Mens khat aktiverte stress proteiner, som p38 og p53, og 
induserte cytotoksiske effekter, resulterte khat amfetaminene i reduserte nivåer av 
aktiverende modifikasjoner hos flere signalproteiner, inkludert p53, og ble vist å ha en 
stimulerende effekt på lymfocytt proliferasjon.    
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Abbreviations    
  
AIF apoptosis inducing factor  
AML acute myeloid leukemia 
ATP adenosine triphosphate 
Bax Bcl-2 associated X protein 
Bcl-xL B-cell lymphoma extra long
Bcl-2               B-cell lymphoma gene 2 
BH Bcl-2 homology 
BID BH3 interacting domain death agonist 
Caspase cysteine aspartate proteinase 
CHX cycloheximide 
CPT camptothecin 
CREB cAMP response element binding 
DISC death inducing signaling complex 
DMSO dimethylsulphoxide 
ERK extracellular signal-regulated kinase 
FLICE FADD-like IL-1-converting enzyme 
FLIP FLICE inhibitory protein 
FLT3 fms-like tyrosine kinase 3  
GS-MS gas chromatography-mass spectrometry 
HPLC high pressure liquid chromatography 
IM inner membrane 
IMS  inter membrane space 
MAPK mitogen-activated protein kinase 
Mcl-1              myeloid cell leukemia-1 
Mdm2            minute double murine 2 
MLL multiple lineage leukemia 
MOMP mitochondrial outer membrane permeabilization 
MPT mitochondrial permeability transition 
MS mass spectrometry  
OM outer membrane 
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PBMC peripheral blood mononuclear cell 
PFA paraformaldehyde 
PMA phorbol myristate acetate 
PTM                post translational modification 
PTP permeability transition pore 
PUMA p53-upregulated modulator of apoptosis  
ROS reactive oxygen species 
RTK receptor tyrosine kinase 
STAT signal transducer and activator of transcription 
TEM transmission electron microscopy 
VDAC voltage dependent anion channel 
WST-1 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium monosodium salt 
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1. INTRODUCTION 
1.1 Plants in medicine 
Plants have been used for both medicinal and recreational purposes for thousands of years. 
Medicinal plants were traditionally used as crude preparations, like teas and powders, in 
treatment and prevention of diseases. In modern Western medicine the drug discovery 
process from plants typically involves isolation and characterization of the active 
component(s) from crude extracts. The concept of isolating bioactive components started 
with the preparation of the alkaloid morphine from opium in the early 19th century. In 
Western medicine it is conventional to use single ingredient drugs or combinations of several 
characterized drugs. The combination therapies are designed to target several pathological 
pathways simultaneously, thereby increasing treatment efficacy. Combination strategies have 
proven particularly suited for treatment of infectious diseases like HIV, tuberculosis and 
malaria, and in therapeutic interventions for complex chronic diseases like cancer and 
metabolic syndrome (1, 2).  
It has been reported that 25% of all drugs prescribed today are derived from plants. 
Out of many families of secondary metabolites, nitrogen-containing alkaloids have 
contributed the largest number of drugs to the modern pharmacopeia. Most drugs isolated 
from plants or that are derivatives thereof are employed in the fight against cancer (1, 2). 
Anti-cancer drugs from plants in current use can be categorized into four main classes of 
compounds: vinca alkaloids, epipodophyllotoxins, taxanes and camptothecins (1). The 
process of drug discovery has been estimated to take an average of 10 years upwards. Drug 
discovery from plants has traditionally been an even slower process, being inherently more 
complicated than modern drug discovery techniques. As a result, pharmaceutical companies 
have been observed to eliminate or scale down their natural product research over the last 
decades (3).  
Today the identification of compounds with therapeutic potentials is typically based 
on high-throughput screening (HTS) platforms, which in part relies on the use of cell-free 
bio-assays. However, there has recently been more emphasis on development of cell-based 
screening techniques. One of the techniques that are being developed and refined is the 
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method of multi-parameter single cell analysis of intracellular signaling pathways (4). The 
development of technical platforms that enable more efficient identification of novel 
compounds form natural sources is believed to re-strengthen the interest in natural products 
as an invaluable source for novel therapeutics. 
1.2 Khat (Catha edulis Forsk.) - a natural stimulant 
Khat (Catha edulis Forsk.) is an evergreen shrub of the Celastraceae family that is cultivated 
primarily for its use as a natural stimulant. The habit of khat chewing is practised by millions 
of people, particularly in Yemen, Somalia, Ethiopia, Djibouti and Kenya, representing main 
regions of cultivation (5, 6). The habit is spreading to other parts of the world, but is mainly 
confined to immigrant communities from countries where khat chewing is endemic (6, 7). In 
addition to its use as a social and recreational drug, processed leaves and roots of khat are 
used in treatment of various conditions like influenza, cough, asthma, malaria, gonorrhoea, 
vomiting and headache (6, 8). 
Figure 1. Bundle of khat on a banana leaf. The banana leaf is wrapped around the bundle in order to 
keep the leaves and shoots fresh. 
Khat chewing is predominantly a social habit, which is practiced in special khat 
chewing sessions, where different issues are discussed and resolved. Fresh leaves and shoots 
of khat are chewed slowly and the juice of the material swallowed while the plant residue is 
retained as a quid on one side of the mouth. About 100-200 g of khat is typically chewed per 
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person in one session, which usually lasts for 3-4 hours, but the amount may vary 
extensively. Khat induces a mild euphoric state giving the chewer a feeling of being more 
focused, energetic and communicative. Labourers, farmers and students are known to use 
khat during work in order to increase alertness and reduce physical fatigue (6, 7).   
1.3 The natural khat amphetamines 
The stimulating effects of khat are mainly due to its content of the alkaloid S-(-)-cathinone, 
and to a lesser extent the diastereomers (1S,2S)-(+)-cathine and (1R,2S)-(-)-norephedrine (9, 
10). Cathinone is an intermediate in the biosynthesis of cathine and is found mainly in young 
leaves of the khat plant. Cathinone is also converted to cathine upon wilting of the khat 
leaves. Khat is therefore consumed when it is fresh and it is primarily the young leaves and 
shoots that are harvested (9). The price of khat at markets in Ethiopia, Kenya and Yemen 
have been reported to correlate with the content of cathinone (11).  
Figure 2. Structures of the natural khat amphetamines: cathinone, cathine and norephedrine, the 
synthetic drug amphetamine and the neurotransmitter noradrenaline.   
Cathinone is structurally related to the synthetic drug amphetamine and has been 
shown to have a similar pharmacological profile. Due to this similarity, cathinone has been 
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termed a natural amphetamine and khat an amphetamine-like stimulant (5, 9). Cathinone and 
amphetamine induce central nervous system and peripheral effects like euphoria, 
hyperactivity, restlessness, mouth dryness, mydriasis, anorexia, hyperthermia, hypertension 
and tachycardia (5, 7, 9). The structures of cathinone and amphetamine are related to 
monoamine neurotransmitters, and the compounds mediate their effects mainly by acting as 
indirect symphatomimetics (Figure 2). Cathinone and amphetamine induce release of 
neurotransmitters (i.e. noradrenaline, dopamine and serotonin) from pre-synaptic neuronal 
terminals and inhibit their reuptake from the synaptic gap (12). Cathinone has also been 
shown to bind and activate 2-adrenergic and 5HT7 serotonin receptors (13, 14).  
The stimulating khat amphetamines are efficiently extracted into saliva during 
chewing, with only 10% of the compounds remaining in the plant residue (15). The oral 
buccal mucosa plays a major role in absorption of the khat amphetamines, but some 
absorption may also occur via the stomach and the small intestine. Maximal blood plasma 
concentrations of the amphetamines following experimental khat chewing have been 
measured after 2.3 hours for cathinone, 2.6 hours for cathine and 2.8 hours for norephedrine 
(15). The khat amphetamines can be detected in urine by gas chromatography-mass 
spectrometry (GS-MS), and it has been shown that less than 7% of ingested cathinone is 
secreted, while norephedrine is found in larger quantities than the amount ingested (16). The 
ratios of the khat amphetamines reflect the preferred in vivo metabolism of cathinone to 
norephedrine (17). GS-MS has also been used to determine the concentrations of the khat 
amphetamines in hair from khat chewers, and their concentrations were reported to reflect 
the level of khat consumption (18, 19). 
1.4 Chemical composition of khat 
The chemical composition of khat is influenced by local conditions, geographical region and 
the time of season in which it is grown. In addition, numerous khat variants exist which 
demonstrate considerable differences in general appearance and stimulating potential (7). An 
analysis of 22 khat samples demonstrated that 100 g fresh khat on average contains 36 mg 
cathinone, 120 mg cathine and 8 mg norephedrine (11). However, the concentrations of the 
khat amphetamines were observed to vary extensively between the different samples.  
In addition to the khat amphetamines, khat contains a family of alkaloids with 
molecular weights in the 600-1,200 range termed cathedulins (20). Liquid 
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chromatography/mass spectrometry demonstrated the presence of 62 cathedulins in methanol 
extracts of khat (21). A third group of alkaloids has been isolated from khat grown in the 
Meru district in Kenya, which include the phenylpentenylamines merucathine, 
merucathinone and pseudomerucathine. Cathedulines and phenylpentenylamines are not 
believed to possess significant biological activity (22). The pigmented root-bark contains 
triterpenoid quinones including celastrol, pristimerin, iguesterin and tingenone (20). 
Tingenone has also been isolated from khat callus cultures, in addition to 22 -
hydroxytingenone (23). Khat contains polyphenols, where especially tannins have been 
found to be present in considerable quantities: 7-14% by weight in dried leaves depending on 
khat cultivate and method of estimation (5). Khat has been shown to contain -sitosterol and 
its glycoside derivatives (10), in addition to flavonoids (24, 25), which include myricetin and 
quercetin glycosides (5). The ascorbic acid content of khat has been reported to be high, with 
100 g of fresh leaves containing 130-160 mg (5). Minor constituents of khat not believed to 
mediate biological effects include -carotene, thiamine, riboflavin, niacin and calcium (5).  
1.5 Adverse health effects associated with habitual khat use 
Khat chewing is associated with the development of oral keratotic white lesions within the 
vestibule or buccal mucosa, where the khat quid is placed (26). A study reported several 
histopathological changes, but none of the lesions were considered to be premalignant (27). 
However, several studies have indicated a correlation between the khat habit and 
development of oral cancer and squamous cell carcinomas of head and neck (28, 29). It has 
been suggested that khat use, in combination with alcohol and tobacco consumption, 
represents a potential cause of malignant transformation (30).  
Khat chewers experience different gastrointestinal problems like gastritis and 
constipation, believed to be caused by the astringent nature of khat tannins (5). Khat chewing 
has been indicated as a risk factor for development of duodenal ulcers (31). The development 
of haemorrhoids is shown to be significantly associated with the khat habit (32). Khat 
mediates hypertension and tachycardia, and it has been demonstrated that chewers have an 
increased risk for acute myocardial infarction (AMI) (33). Cathinone has been shown to 
cause coronary and aortic vasoconstriction, indicating its involvement in myocardial 
infarction (34). Amphetamine has also been suggested to increase the incidence of AMI, and 
was reported after intravenous injection of the drug (35).  
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A range of adverse health effects associated with khat chewing has been reported, 
affecting the cardiovascular, gastrointestinal, hepatobiliary, genitourinary, respiratory and 
central nervous systems. Khat use has also been shown to mediate metabolic, endocrine, 
ocular and psychiatric effects. The many adverse effects associated with khat use have 
recently been reviewed elsewhere (6, 8, 36, 37).  
1.6 Potential beneficial effects by khat and its constituents  
Although khat-chewing is primarily associated with adverse health effects, positive effects of 
khat and its constituents have been reported. Processed leaves and roots of khat have been 
used to treat influenza, cough, asthma and other chest problems in areas of cultivation (6, 8). 
Cathinone was recently shown to inhibit acetylcholine release and contractions of smooth 
muscle, which could explain the use of khat as a remedy for respiratory diseases (13). Long 
term exposures of rabbits to khat resulted in lowered cholesterol, glucose and triglyceride 
concentrations in blood plasma (38). Cathine and norephedrine have been shown to 
accelerate sperm capacitation and inhibit spontaneous acrosome loss, indicating a beneficial 
effect on fertility (39). Khat users in Somalia were reported to have increased lymphocyte 
counts and percentage CD4 positive cells, suggesting a stimulating effect on the immune 
system (40). Cathinone was shown to mediate IL-2 production, B-lymphocyte proliferation 
and cytotoxic T-lymphocyte induction (41). 
A beneficial impact on oral health has been indicated, as the caries prevalence 
amongst khat chewers is reported to be low. Recently, khat extracts were shown to inhibit 
biofilm formation by the principal cariogenic bacterium in humans, Streptococcus mutans, 
suggesting anti-cariogenic properties (42). In addition, khat extracts were found to possess 
selective anti-microbial properties, being particularly toxic to periodontal disease-associated 
bacteria (43). Khat flavonoids have been shown to possess significant anti-inflammatory 
activity in rats, comparable to the standard anti-inflammatory drug oxyphenbutazone (24). 
Another study demonstrated that khat flavonoids possessed antioxidant properties for 
oxidative stress generated during restraint stress in rats (25).  
Khat contains vitamin C, which in addition to being an antioxidant has been shown to 
have anti-cancer effects in vivo in a process involving generation of reactive oxygen species 
(ROS) (44, 45). Compounds mediating cell death possess a toxic potential, but could also 
represent promising anti-cancer therapeutics. Callus cultures of khat were reported to contain 
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the triterpenoids tingenone and 22 -hydroxytingenone, which demonstrated anti-bacterial 
activities and mediated cell death in various cancer cell lines (23). Khat also contains the 
triterpenoid celastrol, which has been shown to possess both anti-inflammatory and anti-
leukemic activities (46). Celastrol was recently reported to induce apoptosis in leukemic 
stem cells, which are implicated in disease relapse (47, 48). The triterpenoid pristimerin has 
been shown to induce cell death by mitochondrial targeting in breast cancer cells (49), via 
proteosomal targeting in prostate cancer cells (50), and it has also been shown to inhibit 
proliferation of leukemic cells (51). An overview of khat constituents and reported beneficial 
effects is provided in Table 1. 
Table 1. Compounds found in khat with potential therapeutic effects.  
Khat constituent: Biological effect: Reference: 
Alkaloids 
• cathinone IL-2 production, B-lymphocyte proliferation, cytotoxic T-
lymphocyte induction, acetylcholine release 
(13, 41) 
• cathine acceleration of sperm capacitation, inhibition of 
acrosome loss 
(39) 
• norephedrine acceleration of sperm capacitation, inhibition of 
acrosome loss 
(39) 
Flavonoids 
• myricetin antioxidant, anti-cancer, anti-inflammatory (52, 53) 
• quercetin antioxidant, anti-inflammatory (54) 
Phytosterols 
• -sitosterol lowers blood cholesterol, anti-cancer (55, 56) 
Sugar acids 
• ascorbic acid antioxidant, anti-cancer (44, 45) 
Triterpenoids 
• celastrol anti-cancer, anti-inflammatory (46, 47) 
• pristimerin anti-cancer (49-51) 
• tingenone anti-microbial, anti-cancer (23) 
• 22 -hydroxytingenone anti-microbial, anti-cancer (23) 
1.7 Toxic effects by khat and underlying mechanisms
Most studies have focused on the pharmacology of khat and the khat amphetamines, whereas 
relatively few reports have investigated potential cytotoxic effects and underlying 
mechanisms. Khat and the alkaloid fraction were shown to produce oxidative stress and 
toxicity in rats by reducing the levels of free radical scavenging enzymes and glucose (25). It 
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was recently reported that khat inhibited ROS scavenging enzymes in blood serum from 
human chewers, resulting in significant elevations in free radical loads (57).  
Khat has been shown to affect blood formation and cause bone marrow suppression 
in mice, while reducing the mitotic index of somatic cells and inducing chromosomal 
aberrations (58). A study using the micronucleus test to evaluate khat-mediated genetic 
damage in humans reported that khat use, especially in combination with alcohol and 
tobacco, could be a potential cause of oral malignancy (30). An organic khat extract was 
shown to induce tumour suppressor proteins and G1 cell cycle arrest in normal oral 
fibroblasts and keratinocytes in vitro (59). When exposed to a higher concentration of khat 
the oral fibroblasts and keratinocytes underwent programmed cell death in a process 
involving ROS (60). Khat-mediated cell death in normal oral fibroblasts and keratinocytes 
was recently reported to involve an early effect on mitochondrial integrity and function (61). 
We previously reported that an organic extract of khat induced cell death in acute 
myeloid leukemia (AML) cell lines in vitro (62). Normal peripheral blood mononuclear cells 
(PBMCs) were shown to be less sensitive to khat toxicity when compared to AML cell lines. 
The process involved caspase-activation and could be blocked by cycloheximide (CHX), an 
inhibitor of protein synthesis. Khat-meditated cell death was reduced by treatment with 
inhibitors of caspase-8, indicating involvement of cell surface death receptors. The khat 
amphetamines were suggested to be partly responsible for the toxic effects of khat in the HL-
60 cell line (62, 63). The studies on AML cell lines and PBMCs suggested that khat could 
contain compounds with potential as anti-cancer therapeutics, and provided the basis for the 
work in this thesis. Table 2 provides an overview of toxic effects of khat extracts and 
suggested underlying mechanisms and/or proposed khat constituents. 
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Table 2. Toxic effects by khat extracts in various systems and responsible mechanisms or constituents.  
Toxic effect by khat: Biological system: Mechanism/constituent: Reference: 
induction of cell cycle arrest primary human oral 
keratinocytes and 
fibroblasts 
activated p53, p16 and p21  (59) 
induction of cell death primary human oral 
keratinocytes and 
fibroblasts 
loss of mitochondrial inner 
transmembrane potential, ROS 
(60, 61) 
induction of cell death  human acute myeloid 
leukemia cell lines 
caspase-activation (62) 
induction of cell death  human cancer cell lines due to tingenone and  
22 -hydroxytingenone 
(23) 
increased ROS human serum, in vivo inhibition of ROS scavengers (57) 
increased ROS rat blood, in vivo reduced levels of ROS scavengers, 
due to the alkaloid fraction? 
(25) 
genetic damage human buccal and 
bladder mucosa cells 
(30) 
genetic damage mice, in vivo  (58) 
anti-bacterial bacteria due to tingenone and  
22 -hydroxytingenone 
(23) 
anti-bacterial oral bacteria  (43) 
1.8 Acute myeloid leukemia cell lines in toxicity studies   
Cell lines are frequently used in investigations of compounds with toxic and therapeutic 
potentials. We previously used AML cell lines when studying cellular and molecular effects 
of khat extract and the khat amphetamines. In addition to representing a model system for 
AML, the cell lines represent systems that are easy to maintain and manipulate. Different 
AML cell lines that are characterized by various genetic defects are commercially available. 
The genetic aberrations may be used as tools when mechanisms underlying cellular effects 
are investigated.  
AML is a hematological malignancy involving uncontrolled proliferation of myeloid 
progenitors that harbour a differentiation block (64). An overview of normal hematopoiesis 
is provided in Figure 3.  
22
Figure 3. Overview of normal hematopoiesis: the generation of mature lineage-specific blood cells 
from a common hematopoietic stem cell. The figure is from Line Wergeland’s PhD thesis, UoB, 
Bergen, Norway, and is printet with her permission.
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A two-hit model for AML development has been proposed, where the genetic 
aberrations are divided into two complementary groups (65). Class I includes mutations that 
activate signal transduction pathways, resulting in enhanced proliferation/survival of 
leukemic progenitors. Class II comprises mutations affecting transcription factors and/or 
transcriptional co-regulators, resulting in impaired differentiation and escape from apoptosis. 
An overview of class I and class II mutations is provided in table 3. 
Table 3. Overview of complementary class I and class II mutations that cooperate in  
development of AML. Adapted from (66). 
Class I mutations Class II mutations 
BCR-ABL CBF-MYH11 
N-RAS AML1-ETO 
K-RAS TEL-AML1 
c-KIT (exon 8) PML-RAR
c-KIT (Asp816) NUP98-HOXA9 
FLT3 (ITD) PU.1 
FLT3 (Asp 835) C/CEP
PTPN11 AML1 
NF1 AML1-AMP19 
TEL-PDGFR MLL fusion proteins 
AML is a heterogeneous disease characterized by non-random genetic defects. 
Approximately 55% of adult patients display chromosomal trans-localizations and 
cytogenetics represents the most important prognostic factor predicting therapy response and 
overall survival. AML patients are broadly divided into three risk groups based on 
cytogenetics with favourable, intermediate and adverse prognosis (67-69). Approximately 
45% of AML patients present cytogenetically normal (CN) myeloblasts at the time of 
diagnosis. Risk stratification and determination of therapeutic strategy in CN-AML patients 
is based on the presence or absence of specific mutations (70). Various mutations that affect 
oncogenes, tumour suppressors and transcription factors are frequently found in AML. 
Several of these mutations represent independent prognostic factors, in addition to providing 
potential therapeutic targets.  
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1.9 Prognostic factors and therapeutic targets in AML 
Mutations in the nucleophosmin 1 (NPM1) gene are found in 45-62% of CN-AML patients, 
representing the most frequent genetic alteration in this subset. The NPM1 protein is 
activated by phosphorylation and is involved in diverse processes related to proliferation, 
growth suppression and differentiation (71). Approximately 40% of patients harbouring 
mutations in NPM1 also carry internal tandem duplications (ITDs) in the FLT3 gene 
encoding the Fms-like tyrosine kinase 3 receptor. NPM1 mutations represent a favourable 
prognostic marker, but only in the absence of FLT3-ITDs (70). The FLT3 receptor is 
constitutively activated in approximately 30% of AML patients by ITDs, representing an 
independent prognostic factor which confers a poor prognosis (72).  
Constitutive activation of receptor tyrosine kinases (RTKs), like FLT3 and c-KIT, 
causes aberrant signaling via intracellular cascades meditated by phosphorylation of 
signaling proteins. Signaling proteins frequently found to be acitvated in cancers include 
members of the family of signal transducers and activators of transcription (STATs), the 
Ras/mitogen-activated protein kinases (MAPKs) and the PI3K/AKT pathway (73). The 
transcription factor STAT5 is constitutively activated in cells with FLT3 mutations (74) and 
has been shown to induce transcription of survival proteins like Bcl-2 and Bcl-xL (75, 76). 
Over-expression of surval proteins frequently mediates chemoresistance and poor overall 
survival. 
 Several of the recurring genetic aberrations and deregulated pathways in AML 
represent potential therapeutic targets. Small molecules that inhibit the activity of 
constitutively activated RTKs are being evaluated for treatment in clinical trials, and 
strategies that target down-stream effects like over-expressed survival proteins are being 
investigated. Detailed reviews on prognostic markers and therapeutic targets in AML have 
recently been published (70, 73, 77). 
1.10 Treatment of AML  
Conventional AML treatment consists of induction therapy where a combination of an 
anthracycline or anthracenedione (daunorubicin, idarubicin, mitoxantrone) and cytarabine-
arabinoside (cytarabine) is administered. A majority of patients receiving intensive 
chemotherapy will achieve complete remission, defined as less than 5% myeloblasts in the 
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bone marrow, after initial induction treatment (64, 78). The patients will then receive 
consolidation therapy with either allogeneic stem cell transplantation or repeated cycles of 
intensive chemotherapy. Allogeneic stem cell transplantation and high-dose cytarabine 
represent the most intensive therapeutic approaches, but serious side-effects and high 
treatment-related mortality make these interventions possible only for patients below 60 
years of age (64, 78). Patients up to 70 years of age are often treated with less intensive 
chemotherapy and patients above 70 years usually receive supportive therapy alone, the 
median survival of these patients being 3-4 months (64, 78). Overall AML free survival is 
40-50% even for the younger patients who receive the most intensive chemotherapy, and the 
most important cause of death is therapy-resistant leukemia relapse (78). AML relapse is 
believed to be caused by acquisition of drug resistance and/or failure of the treatment to 
target AML stem cells (48). 
1.11 Programmed cell death 
Anti-cancer interventions may be opposed by numerous genetic alterations, which frequently 
affect pathways of programmed cell death (79-81). The aim in therapeutic interventions is 
often restoration of the ability of cancer cells to undergo programmed cell death (82).  
Programmed cell death was previously considered synonymous with the term 
apoptosis (83). Apoptosis was pictured to be induced either via an extrinsic (receptor-
mediated) or an intrinsic (mitochondria-mediated) pathway, which converged on activation 
of cellular proteinases termed caspases (cysteine-aspartate proteinases). The caspases 
catalyze cleavage of cellular proteins, mediate DNA-degradation and cause cell destruction 
(84). However, it is now evident that programmed cell death may occur through other 
regulated sequences of events, with or without the involvement of caspases. 
According to the recommendations by The Nomenclature Committee on Cell death 
2009, programmed cell death can be broadly divided into apoptosis, autophagy and necrosis 
(85). The morphological features characteristic for apoptosis include reductions in microvilli, 
cellular and nuclear shrinkage, chromatin condensation, nuclear fragmentation, little or no 
ultra structural changes in cytoplasmic organelles and plasma membrane blebbing. Even if 
caspase-activation is no longer considered a hallmark of apoptosis, it may be necessary for 
acquisition of the characteristic apoptotic morphology (86).  
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Autophagy is characterized by the formation of authophagic vacuoles, which are 
double-membrane vesicles containing cellular organelles, proteins and cytoplasm. Upon 
fusion with lysosomes the autophagosome inner membrane and the sequestered material is 
degraded, resulting in recycling of building blocks and generation of cellular energy. The 
catabolic step marks the completion of the autophagic pathway. Autophagy is triggered in 
times of nutrient deprivation and also occurs as a means of degrading damaged organelles 
(87, 88). It primarily represents a cell survival mechanism, but has in addition been 
demonstrated to mediate cell death (89).  
Necrosis was originally considered to be an accidental and uncontrolled mode of cell 
death, but has now been shown to involve regulated sequences of events (90). Morphological 
characteristics include gain in cell volume, swelling of organelles, plasma membrane rupture 
and loss of intracellular contents. An overview of morphological characteristics of the three 
main modes of programmed cell death is provided in Table 4.  
Table 4. Simplified overview of morphological characteristic of the main modes of cell death 
according to the recommendations by The Nomenclature Committee on Cell death 2009 (85).  
Mode of cell death: Morphological characteristics: 
Apoptosis Reduction of microvilli 
Reduction of cellular and nuclear volume 
Nuclear fragmentation 
Minor modifications of cytoplasmic organelles 
Plasma membrane blebbing 
Autophagy Lack of chromatin condensation 
Vacuolization of the cytoplasm 
Formation of autophagic vacuoles 
Necrosis Cytoplasmic swelling 
Rupture of plasma membrane 
Swelling of cytoplasmic organelles 
Moderate chromatin condensation 
Morphological characteristics represent the basis for discriminating between 
apoptosis, autophagy and necrosis. Various molecular events have been demonstrated in the 
different modes of cell death, but a set of biochemical critera that may be used to 
discriminate between them remains to be defined.  
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1.12 Mitochondria in cell death regulation 
Mitochondria are highly specialized organelles consisting of an extensively folded inner 
membrane (IM), an intermembrane space (IMS) and an outer membrane (OM). The IM 
contains the mitochondrial respiratory chain consisting of four protein complexes involved in 
adenosine triphosphate (ATP) production through the process of oxidative phosphorylation. 
The IMS contains various cell death agonists, and the OM harbours proteins functioning as 
ion pumps and regulators of its stability. In addition to its prominent role in energy 
production, mitochondria play a central role in regulation of programmed cell death (91-93).  
The stability of the OM is regulated by the Bcl-2 family of proteins, and 
mitochondrial OM permeabilization (MOMP) results in release of IMS cell death agonists to 
the cytoplasm (94). IMS proteins include caspase-activators like cytochrome c, 
Smac/DIABLO and Omi/HtrA2, and caspase-independent factors like apoptosis inducing 
factor (AIF) and endonuclease G (95). The IMS proteins have been shown to further promote 
cell death by antagonizing inhibitors of apoptosis proteins (IAPs). Cytochrome c is normally 
involved in mitochondrial ATP production, but when released into the cytosol it complexes 
with apoptosis protease-activating factor (Apaf-1), ATP and procaspase-9 to form the 
apoptosome. A simplified overview of mitochondria-mediated cell death is provided in 
Figure 4. 
The exact molecular mechanism underlying MOMP is still not defined. An increase 
in permeability of the IM to solutes with molecular masses less than 1,500 Da has been 
shown to result in loss of mitochondrial membrane potential, mitochondrial swelling and 
rupture of the OM (96). This process is termed the mitochondrial permeability transition 
(MPT), and the mitochondrial permeability transition pore (PTP) has been suggested to play 
an important role (97). 
Another mechanism by which mitochondria participate in cell death induction is via 
production of excess levels of intracellular ROS (91, 92). The mitochondrial respiratory 
chain contains several red-ox centres that leak electrons to molecular oxygen, resulting in 
generation of oxygen radicals. The cell converts oxygen radicals into hydrogen peroxide or 
other ROS, before elimination by cellular antioxidant systems including glutathione GSH 
and thioredoxins. ROS production by the mitochondrial respiratory chain has been shown to 
cause damage to proteins, DNA and mitochondrial membranes, resulting in MOMP and cell 
death (98). 
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Figure 4. Simplified overview of mitochondria-mediated cell death 
1.13 Bcl-2 family proteins and programmed cell death 
The Bcl-2 family of proteins consists of anti-apoptotic and pro-apoptotic members involved 
in regulation of cell survival and death (94). The impact on mitochondrial OM stability and 
induction of MOMP represent the best studied processes involving Bcl-2 proteins.  
The founding member of the Bcl-2 family is the anti-apoptotic Bcl-2 protein, which 
was discovered by characterization of genes involved in the 14;18 translocation found in 
follicular non-Hodgkin B-cell lymphoma (99). The Bcl-2 proteins contain 1 to 4 conserved 
Bcl-2 homology (BH) domains and are divided into: 1) anti-apoptotic proteins consisting of 
BH domains 1-4 (Bcl-2, Bcl-xL, Mcl-1, A1/Bfl-1), 2) pro-apoptotic proteins containing BH 
domains 1-3 (Bax, Bak, Bok/Mtd) and 3) pro-apoptotic proteins with only BH domain 3 
(BH3-only proteins; e.g. BID, Bad, Noxa, PUMA)(94). The BH3 domain represents the 
region that allows interaction between Bcl-2 family members, and is also found in other 
proteins that interact with Bcl-2 proteins (100, 101).  
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The pro-apoptotic Bax and Bak proteins perturb mitochondrial integrity by forming 
homo-oligomers which function as pores in the OM (102, 103). Anti-apoptotic Bcl-2 family 
members antagonize Bax and Bak and stabilize the mitochondrial OM by forming 
heterodimers with the pro-apoptotic proteins (104). The BH3-only members favour pore-
formation by Bax and Bak by antagonizing anti-apoptotic Bcl-2 proteins (105). If the balance 
between anti- and pro-apoptotic Bcl-2 family proteins is shifted towards the pro-apoptotic 
branch, the result is MOMP, which releases IMS death agonists into the cytosol (94). Bcl-2 
family members have also been shown to associate with components of the PTP, which 
transverses both the mitochondrial IM and OM (97). Pro-apoptotic Bcl-2 family proteins like 
Bax, Bak and tBID have been suggested to induce pore opening by interacting with the 
voltage dependent anion channel (VDAC), whereas anti-apoptotic Bcl-xL induces its closure 
(106-108). 
The anti-apoptotic Bcl-2 protein is frequently over-expressed is hematologic 
malignancies, including AML, where it confers chemotherapeutic resistance (109, 110). Bcl-
2 and Bax levels have been shown to correlate with spontaneous apoptosis in AML cells in 
vitro (81), and the Bax/Bcl-2 ratio in de novo AML patients has been reported to predict 
clinical response and outcome (79). Targeting of anti-apoptotic Bcl-2 family members, like 
Bcl-2 and Bcl-xL, represents a promising therapeutic strategy where different approaches are 
being explored. A range of small molecule inhibitors of anti-apoptotic Bcl-2 proteins has 
been identified by screening of natural compounds and rational design techniques (111). 
Examples of potent inhibitors include Gossypol, Apogossypol and HA14-1 (112-114). Bcl-2 
over-expression antagonizes both apoptosis and necrosis, and it has been shown to inhibit 
Beclin-1-dependent autophagy when localized in the ER (115). It has been suggested that 
Bcl-2 suppresses autophagy to levels that are compatible with cell survival rather than cell 
death (116). 
The anti-apoptotic Mcl-1 protein has also been found to be over-expressed in cancers, 
mediating resistance to cell death-induction (117-119). Mcl-1 degradation is required for 
MOMP following UV irradiation (120) and therapeutic targeting of Bcl-2 family members 
has been shown to depend on Mcl-1 neutralization (121). Anti-apoptotic Mcl-1 has also been 
demonstrated to bind Beclin-1, which contains a BH3-like domain (101, 122).  
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1.14 Induction of death via cell surface receptors 
Cell death may be induced by signals from within the cell (e.g. DNA damage, hypoxia, ROS) 
or by activation of cell surface death receptors of the tumor necrosis factor (TNF) 
superfamily of receptors. Binding of extracellular death ligands result in receptor-
oligomerization and recruitment of intracellular adaptor proteins and procaspase-8. Together 
these components constitute the death inducing signaling complex (DISC), where  
procaspase-8 becomes activated and mediates cleavage-activation of down-stream effector 
caspases (82). Additionally, caspase-8 cleaves the BH3-only pro-apoptotic Bcl-2 family 
member BID to truncated (t)BID, generating the activate version of this cell death agonist 
(123). tBID promotes mitochondrial cytochrome c release and connects the receptor-
mediated and the mitochondria-mediated cell death pathways (123, 124). The anti-apoptotic 
Mcl-1 protein has been shown to interact with and counteract the death inducing activity of 
tBID (125).  
Cellular FLICE (FADD-like IL-1-converting enzyme)-inhibitory protein (c-FLIP), a 
catalytic inactive caspase-8 homologue, has been shown to antagonize receptor-mediated cell 
death at the DISC (126, 127). FLIP primarily localizes to the cytosol and is expressed as 
three isoforms, c-FLIPs and c-FLIPR, representing two short forms and c-FLIPL, which is a 
full length version. Most reports have demonstrated that c-FLIPL inhibits receptor-mediated 
death, but a potential role in the NK-B survival pathway has been suggested (128). A 
simplified overview of receptor-mediated cell death is provided in Figure 5. 
c-FLIP over-expression provides resistance to receptor-mediated apoptosis in B cell 
chronic lymphocytic leukemia, multiple carcinomas (e.g. colourectal, gastric, pancreatic and 
ovarian) and Hodgkin/Reed-Sternberg cells (129-131). Down-regulation of c-FLIP levels 
sensitizes tumour cells to apoptosis-induction by extracellular death ligands (132-134). 
Various anti-cancer drugs including doxorubicin, actinomycin D, cycloheximide (CHX) 
camptothecin (CPT) and bortezomib have been shown to mediate reduced c-FLIP levels 
(129, 135). Phenoxodiol, a synthetic analogue of a soybean isoflavone, has been reported to 
inhibit XIAP and c-FLIP, and represents a potential anti-cancer therapeutics (136, 137). 
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Figure 5. Simplified overview of receptor-mediated cell death and its relation to the mitochondria-
mediated pathway. 
1.15 p53 - stress sensor and tumour suppressor 
The p53 protein is a sequence-specific transcription factor that can halt progression through 
the cell cyle or initiate cell death in response to DNA-damage and other types of cellular 
stress (138). p53 has a prominent role as a tumour suppressor and is found mutated and 
inactivated in over 50% of human cancers (139-141). However, p53 is most often wild type 
(wt) in hematological malignancies, and less than 10% of AML patients carry p53 mutations 
at the time of diagnosis (142, 143). The prevalence of p53 mutations is found to be higher in 
secondary AML and increases with patient age (139).  
p53 has a short half-life in non-stressed cells due to its interaction with the human 
double minute protein (Mdm2), which is a p53-specific E3 ubiquitin ligase (144, 145). 
Mdm2-mediated mono-ubiquitination of lysine residues precedes poly-ubiquitination by 
p300, which targets p53 for proteasomal degradation (146-148). Stress signals, including 
DNA-damage, hypoxia and nutrient deprivation, induce various post-translational 
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modifications (PTMs) of p53 affecting its stability, localization and function. p53 contains 
multiple lysine, threonine and serine residues that can accept various modifications, which 
include ubiquitination, phosphorylation, acetylation and sumoylation (138). Phosphorylation 
of serine 15 and 37 in the N-terminal domain is detected rapidly after stress induction, and 
has been shown to inhibit Mdm2-mediated degradation, resulting in p53 stabilization and 
activation (149). Acetylation of lysine residues in the C-terminal domain also inhibits the 
interaction with Mdm2, and has been shown to enhance p53 transcriptional activity, as well 
as to be crucial for its transcription-independent functions (150, 151). 
When acting as a tumour suppressor, the p53 protein may mediate programmed cell 
death via both transcription-dependent and transcription-independent mechanisms. p53 has a 
well known function as a sequence-specific transcription factor that induces expression of 
pro-apoptotic genes of the Bcl-2 family (152-154). The p53-inducible Bax, Noxa and PUMA 
proteins promote MOMP and mitochondria-mediated cell death. In addition, p53 has been 
shown to induce other mitochondrial proteins that favour MOMP through oxidative 
reactions, like ferredoxin reductase and proline oxidase (155, 156). Furthermore, p53 has 
been shown to induce expression of the cell surface death receptor 5 (DR5) following DNA 
damage (157). 
  Stress stimuli have been shown to trigger rapid trafficking of p53 to the 
mitochondria, an effect preceding its nuclear accumulation (158, 159). The mitochondrial 
trans-localization was demonstrated to be induced by Mdm2-mediated mono-ubiquitination 
and not by phosphorylation or acetylation (160, 161). In the OM membrane p53 interacts 
with anti-apoptotic Bcl-2 proteins and inhibits their stabilizing function (159, 162). p53 
disrupts the complex between Bak and Mcl-1, and has been shown to mediate Bak 
oligomerization (163). p53 has also been shown to activate Bax, promoting MOMP and cell 
death induction (164). In addition to direct inhibition of the stabilizing function of anti-
apoptotic Bcl-2 family proteins, p53 may repress transcription of these and other cell death 
antagonists like the IAP protein Survivin (165, 166). Another transcription-independent 
mechanism by which p53 promotes cell death is by mediating cell surface trafficking of the 
TNF receptor Fas (CD95) from cytoplasmic stores (167).  
Cancer cells expressing wt p53 still have the potential to evade induction of 
apoptosis. This is due to the presence of other mutations opposing the death-inducing activity 
of p53. Different mechanisms have been demonstrated and include over-expression of Bcl-2, 
Mdm2 and the human papilloma virus E6 protein, loss of the Mdm2 inhibitor p14ARF and 
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aberrant modulation of p53 by kinases/phosphatases (168, 169). AKT has been reported to 
contribute to chemoresistance by attenuating p53 phosphorylation, which will inhibit its 
stabilization and accumulation (170). MLL translocations represent a poor prognostic factor 
in AML, and a proposed mechanism for MLL fusion proteins involves reduced p53 
acetylation and stabilization (171, 172).  
Activation of p53 and induction of cell death represents a therapeutic target in 
cancers, which may be triggered in response to radiation- and chemotherapy (139, 173). 
Novel non-genotoxic strategies for p53-activation are currently being investigated, examples 
include the Nutlins which are small molecular antagonists of Mdm2-mediated degradation of 
wt p53 (174, 175). Another promising compound is PRIMA-1 which restores the tumour 
suppressing function of mutated p53 (176). Several drugs that target the Bcl-2 protein 
promote MOMP and cell death through mechanisms involving activation of p53 (177). 
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2. AIMS OF THE STUDY 
An organic extract of the natural stimulant khat was previously shown to induce programmed 
cell death in AML cell lines, while being less cytotoxic to normal PBMCs. Few studies have 
aimed at evaluating cellular and molecular events underlying khat toxicity, compared khat 
with a characterized drug or evaluated the effects of khat and known constituents on normal 
immune cells.  
This study was undertaken to:  
• elucidate cellular and molecular effects underlying khat-induced cell death in AML 
cell lines in comparison to a well characterized cancer therapeutics  
• investigate early cellular and molecular effects of khat and the khat amphetamines in 
normal peripheral immune cells 
• identify the compound(s) mediating the cytotoxic effects of the khat extract 
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3. METHODOLOGICAL CONSIDERATIONS   
3.1 Preparation of an organic khat extract  
Various organic solvents have been used for khat extraction in studies of in vitro effects of 
khat. When preparing an extract of khat we used methanol extraction as in the previous 
studies on khat cytotoxicity in AML cell lines (62, 63). The protocol used had been shown to 
produce an extract with appreciable levels of the natural khat amphetamines: cathinone, 
cathine and norephedrine (62). In short, the khat material was extracted with pure methanol, 
the solvents evaporated and the remaining semi-solid residue dissolved in dimethylsulfoxid 
(DMSO) at 0.2 g/ml for storage at -80oC.  
In this study, two different batches of khat from the Meru district in Kenya were 
extracted and used in experiments. The khat grown in Meru is known to be cultivated in the 
traditional way and has not been treated with pesticides. However, there is an ongoing debate 
whether the use of such chemicals should be introduced in Meru (personal communication, 
O.M. Lukandu and S. Kimani; European Science Foundation conference, Linköping, 
Sweden, 2009). Khat farmers in Yemen are using pesticides and there are rising concerns 
about potential adverse health effects derived from its use (57, 178). 
The first khat batch was harvested and processed in February/March 2005, and the 
extract was used in the experiments in paper I and IV. The second khat batch was harvested 
and processed in September/October 2007, and used in experiments in paper II and III. When 
comparing the toxic potentials of the two extracts they were observed to induce similar levels 
of cell death in AML cell lines. However, the extract from 2005 appeared slightly more toxic 
than the extract from 2007 (results not shown). The chromatograms of the two extracts 
displayed similar profiles, indicating a similar chemical composition and a standardized 
extraction procedure (Figure 6). The compositions of the extracts were not expected to be 
identical, since factors like season and variations in growth conditions will influence the 
chemical profile (7).   
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Figure 6. Chromatograms of the khat extracts from 2005 and 2007. The circle indicates elution of the khat 
amphetamines: norephedrine, cathine and cathinone. The figure is based on HPLC analyses performed by K. O. 
Fossan.  
3.2 Experimental concentrations of khat and its amphetamines  
The natural khat amphetamines, and in particular cathinone, represent the most well studied 
constituents of khat. The studies have elucidated the chemistry and pharmacology of the khat 
amphetamines, and dealt with methods for their detection in blood plasma, urine and hair 
(15, 16, 18, 19).  
In this study, AML cell lines and normal peripheral leukocytes/lymphocytes were 
exposed to various dilutions of the khat extracts. The experimental dilution designated 200 
g/ml in paper I is based on the weight of semi-solid khat material dissolved in DMSO (0.2 
g/ml). The 200 g/ml designation hence represents a 1:1000 dilution of the DMSO-solution 
of the khat extract. This designation does not provide information about the actual 
concentrations of khat constituents, and the concentrations of the khat amphetamines were 
therefore determined using high pressure liquid chromatography and tandem mass 
spectrometry (HPLC-MS-MS). Table 5 provides an overview of the concentrations and 
molarities of the khat amphetamines in the khat extracts and in experimental cell cultures.  
Cathinone is relatively unstable and is transformed to cathine upon wilting of khat 
leaves, while being metabolized predominantly to norephedrine in vivo (9, 16, 17). 
Cathinone is therefore suited as a reference substance, indicating the freshness of the 
extracted khat batch and the stability of the extracted material.  
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Table 5. Overview of the concentrations and molarities of the khat amphetamines in the two khat extracts and 
experimental dilutions used in this study.    
Khat extract Cathinone 
(mw 150.1) 
Cathine 
(mw 152.1) 
Norephedrine 
(mw 152.1) 
mg/ml M mg/ml M mg/ml M 
2005 
Stock solution  1.5 0.01 1.4 9.2 x 10-3 0.2 1.3 x 10-3
10-3 dilution  1.5 x 10-3 1.0 x 10-5 1.4 x 10-3 9.2 x 10-6  2.0 x 10-4 1.3 x 10-6 
      
2007 
Stock solution  2.5 0,017 3.0 0.02 0.3 2.0 x 10-3
10-3 dilution  2.5 x 10-3 1.7 x 10-5     3.0 x 10-3 2.0 x 10-5  3.0 x 10-4 2.0 x 10-6
3.16 x 10-4 dilution 7.9 x 10-4 5.4 x 10-6     9.5 x 10-4 6.3 x 10-6 9.5 x 10-5 6.3 x 10-7
10-4 dilution 2.5 x 10-4 1.7 x 10-6     3.0 x 10-4 2.0 x 10-6 3.0 x 10-5 2.0 x 10-7
Maximal serum concentrations following khat chewing have been measured to be, in 
g/l, 58.9 ± 18.8 for cathinone, 71.2 ± 13.9 for cathine and 72.1 ± 12.2 for norephedrine 
(15). Each of the measured serum values correspond to concentrations in the range of 10-7 M. 
It should be noted that the amount of khat chewed by the study participants was one quarter 
of the amount used by an average chewer, and that the amount chewed varies widely (15). 
Due to the efficient extraction of the khat amphetamines into saliva, cells and tissues in the 
oral cavity are exposed to relatively high concentrations of the khat amphetamines (15). 
Previous estimates of cathinone concentrations in saliva suggest that the concentrations of 
khat amphetamines used in this study are within the range of concentrations found in the oral 
cavity (59).  
3.3 AML cell lines and normal peripheral blood leukocytes  
There are many advantages of using cell lines in studies of toxicity and in pre-clinical 
evaluation of cellular and molecular effects by potential drugs. These include ease of 
cultivation, commercial availability, genetic and phenotypic characterization and the 
possibility of comparing results with previous in vitro studies. However, several problems 
are associated with the use of cancer cell lines, like recurrent mycoplasma infections, cell 
line mix-ups and the differences in genetic expression between the cell line and the cancer it 
represents. For instance, most available AML cell lines carry a mutated TP53 gene, which 
contrasts with the disease where p53 is reported to be wt in 90% of the patients (142, 143). 
However, the leukemic cell lines MOLM-13 and MV-4-11 express wt p53 (179, 180), and 
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were therefore used in paper I and II, where khat-induced cellular and molecular events were 
evaluated. Further, the difference these cell lines exhibited in khat sensitivity made them 
valuable when studying the mechanisms underlying khat toxicity. 
The p53 protein was studied in paper II, and in order to establish the functional role 
of p53 activation in khat-mediated cell death, we tested different cell systems with deleted or 
reduced levels of p53. Experiments were performed with bone marrow cells from p53 -/- 
mice and their wild-type littermates (181), and we also used MOLM-13 wt and MOLM-13 
shp53 cells, where the expression level of p53 had been reduced by the introduction of short 
hairpin (sh) RNAs against p53 (182).  
In paper III we investigated early effects by khat and the khat amphetamines on 
intracellular signaling in normal peripheral leukocytes. The use of primary cells enabled us to 
study effects on healthy cells, and in addition provided us with the opportunity to compare 
effects in subsets of a complex population of immune cells. The study provided information 
about effects on normal cells, but further studies using multi-parameter flow cytometric 
analysis could shed light on potential theraperutic effects by the amphetamines, which were 
shown to attenuate activating protein modifications (4). 
3.4 Determination of cell death, viability and proliferation  
Induction of cell death in AML cell lines was determined based on fluorescence microscopy 
of cells that had been fixed and stained with the DNA-intercalating fluorochrome Hoechst 
(183). Normal nuclei displayed a diffuse nuclear staining, whereas non-normal nuclei 
appeared more intensely stained, with or without the nuclear fragmentation characteristic of 
apoptotic cells (85). This method is well established as a routine assay for determination of 
cell death. Ultra structural cellular features were evaluated with transmission electron 
microscopy (TEM), representing a principal method used to distinguish between different 
modes of cell death (85, 90). In paper I, TEM indicated khat-mediated activation of 
autophagy in MOLM-13 cells, with formation of autophagosomes and cytosolic 
vacuolization. In paper II, we stained khat-treated MOLM-13 cells with Lyso Tracker® Red 
DND-99, demonstrating increased levels of acidic cellular organelles, further suggesting 
involvement of the autophagosomal-lysosomal pathway (184). Compared to AML cell lines, 
it is difficult to evaluate nuclear morphology in bone marrow cells and PBMCs following 
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Hoechst-staining. In paper II and III, assessment of cell death in primary cells was therefore 
based on flow cytometric analyses following Annexin-FITC/PI staining. 
Cell viability/proliferation of AML cell lines was evaluated with the WST-1 assay. 
The assay relies on the activity of complex II in the mitochondrial respiratory chain, which 
converts the WST-1 salt (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium monosodium salt) to soluble formazan dye, which can be quantified by 
measuring absorbance (185). The presence of functional mitochondria will therefore provide 
a means of assessing viable and proliferating cells. High-resolution respirometry, which 
measures oxygen consumption by metabolic active mitochondria, was used to complement 
the results based on nuclear morphology, the WST-1 assay and TEM in paper I. The results 
demonstrated that by using different methods to evaluate cytotoxicity, it was possible to 
elucidate the underlying mechanisms of khat-induced cell death. When assessing degree of 
PBMCs proliferation in paper III, we used a 3H-thymidine incorporation protocol based on 
the whole blood assay described by Wendelbo et al. (186, 187). Unfortunately, we did not 
assess the amount of cell death simultaneously as we determined degree of 3H-thymidine 
incorporation. However, khat was shown to induce cell death after 6 hours of exposure based 
on Annexin-FITC/PI staining, and the reduced proliferation of PBMCs seen after 4 days was 
probably in part due to induction of cell death in a fraction or subset of the cells.  
In order to evaluate the cytotoxic potential of khat and underlying mechanisms, khat 
was compared side-by-side with camptothecin (CPT) in paper I and II. CPT is an alkaloid 
that originally was isolated from the Chinese plant Camptotheca acuminata (188). CPT 
induces apoptosis in various cancer cells and its derivatives irinotecan and topotecan are 
currently used as anti-cancer therapeutics (188). CPT mediates topoisomerase I-linked DNA 
breaks by preventing religation and has been shown to induce p53, Noxa and Mcl-1 (189, 
190). CPT and its analogues are collectively termed camptothecins, and represent one of the 
four main classes of anti-cancer compounds from plants (1).  
3.5 Determination of protein levels and signaling events 
Protein levels in AML cell lines were determined primarily using one-dimensional 
polyacrylamide gel electrophoresis (1D-PAGE) and Western blotting in paper I and II. The 
KODAK Image Station 2000R software was used for quantification of Western blots and 
determination of fold change in protein levels. In paper I, where we assessed the impact of 
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khat-treatment on procaspase-8 activation, the Western blot analyses were complemented 
with the use of a colourimetric assay to verify cleavage and enzymatic activation.   
When studying the p53 protein in paper II, we used two-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE) in addition to 1D-PAGE. This technique is superior to 1D-
PAGE when studying expression of various p53 isoforms and levels of PTMs (191, 192). 
When analyzing the 2D images, we used an analysis method that was developed to enable 
correlation of separate analyses and biological variables (193). p53 PTMs were in addition 
analyzed with modification-specific antibodies and flow cytometric analyses as previously 
described (4). The results demonstrated that flow cytometric analyses of the different p53 
modifications represented a more sensitive technique compared to the 1D-PAGE protein 
analyses. 
 Modification-specific antibodies and flow cytometric analyses were also used in 
paper III, when we analysed intracellular signaling events in normal peripheral leukocytes. A 
major advantage of this technique over Western blotting when studying proteins is that it 
enables multi-parameter analyses of intracellular signaling events in complex cell 
populations. It was therefore the natural choice of method when we assessed signaling events 
in subsets of the complex population of immune cells. The many advantages and also the 
challenges associated with this technique have been reviewed by Krutzik et al. (194). 
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4. SUMMARY OF PAPERS 
Paper I
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death 
phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and 
mitochondrial function in acute myeloid leukemia cell lines  
Cellular and molecular effects of khat were investigated using AML cell lines with diverse 
genetic characteristics. The cytotoxic effects of khat were compared with the cancer 
therapeutics camptothecin (CPT), in order to evaluate the toxic potential of khat and to 
elucidate the mechanisms underlying toxicity. The AML cell lines demonstrated varying 
sensitivities to khat, where some cell lines were shown to be sensitive to khat-induced cell 
death whereas others appeared resistant. The different sensitivities could not be correlated to 
endogenous Bcl-2 and Bax levels, or to selected prognostic factors (FLT3 and TP53). Khat 
treatment had a profound effect on mitochondrial structure and function in MOLM-13, in 
contrast to CPT. Khat was observed to induce formation of autophagosomes and cytosolic 
vacuolization in MOLM-13 cells, suggesting activation of autophagy. Khat mediated reduced 
levels of anti-apoptotic Mcl-1 protein in MOLM-13, whereas both khat and CPT were shown 
to activate procaspase-8 and induce cleavage of its endogenous antagonist c-FLIPL.  
Paper II
Modulation of p53 isoforms and its post-translational modifications 
reflect the cytotoxicity of a botanical khat extract  
The effects of khat-treatment on induction of p53 PTMs, on p53 isoform distribution and the 
contribution of p53 in khat-mediated cell death were evaluated. The analyses included the 
khat-sensitive MOLM-13 cell line and the khat-resistant MV-4-11 cell line. p53 was 
subjected to phosphorylations and acetylation in both MOLM-13 and MV-4-11 cells, but its 
accumulation was only demonstrated in MOLM-13. When comparing khat-mediated toxicity 
in bone marrow cells from p53 -/- mice with cells from normal mice, no protective effect 
against khat was observed. Similarly, MOLM-13 cells transduced with shp53 were not more 
resistant to khat-mediated cell death compared to wt MOLM-13 cells. Treatment of the khat 
resistant MV-4-11 cell line with p38 inhibitors increased its sensitivity to khat. Pre-treatment 
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of MOLM-13 cells with p38 inhibitors abolished khat-induced activation of autophagy, 
whereas this pathway was unaffected in MV-4-11. The study indicated that khat acted 
independently of p53, but suggested that p53 isoform pattern and PTMs could be used to in 
identification and characterization of chemical probes and potential anti-cancer therapeutics.    
Paper III
Natural khat-derived amphetamines attenuate phosphorylation of AKT, 
STAT6, CREB and p53 in peripheral leukocytes  
Multi-parameter flow cytometric analyses of signaling proteins were used to investigate early 
responses in normal periperhal leukocytes to treatment with khat and its natural 
amphetamines: cathinone, cathine and norephedrine. The leukocytes were labeled with 
modification-specific antibodies against stress sensor proteins and signal transducers of 
various intracellular pathways (AKT, CREB, ERK1/2, p38, STAT1/3/5/6 and p53). The 
different subsets of the leukocytes: T-lymphocytes, B-lymphocytes/natural killer (NK) cells 
and the myeloid population (neutrophile granulocytes and monocytes) responded differently 
to the various treatments. The khat extract was generally observed to mediate activation of 
signaling proteins, detected as increased levels of phosphorylation and acetylation, whereas 
the khat amphetamines attenuated activating modifications. Khat resulted in increased p53 
and phosphorylated p38, and was observed to induce cell death and reduced proliferation of 
PBMCs, whereas the khat amphetamines appeared to have a stimulating effect on cell 
division.  
Paper IV
Bio-guided isolation of a major cytotoxic constituent in khat (Catha 
edulis Forsk.) unrelated to natural khat amphetamines 
In order to identify the cytotoxic constituent(s) in the khat extract, the extract was subjected 
to high pressure liquid chromatography (HPLC), and the resulting fractions screened for 
toxicity in the khat-sensitive cell lines HL-60 and MOLM-13. The cell-based screen resulted 
in the identification of three separate cytotoxic fractions, mediating reduced 
viability/proliferation and induction of cell death. Both cytotoxic and neutral fractions were 
subjected to mass spectrometry analyses in order to identify the main cytotoxic 
component(s). The presence of the khat amphetamines did not correlate with the cytotoxicity 
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of the khat fractions, and treatment of HL-60 and MOLM-13 with cathinone, cathine and 
norephedrine further suggested that these constituents were relatively non-toxic. The most 
cytotoxic khat fraction contained a molecule with a mass of 1452 Da, and the MS 
fragmentation pattern suggested that the molecule consisted of two central phenylpropanoid 
glycosides with five attached comaryl-groups. This study is the first to describe a cytotoxic 
phenylpropanoid glycoside in an extract of khat.  
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5. GENERAL DISCUSSION 
5.1 Specificity in cell death-induction and genetic aberrations 
Khat was demonstrated to mediate cell death in a subset of genetically diverse AML cell 
lines, in paper I and II. The observations of AML cell lines to be either sensitive or resistant 
to khat suggested involvement of specific death pathways. In contrast to khat, the anti-cancer 
therapeutics CPT was observed to induce cell death in all cell lines tested, although with 
varying efficacies. The specificity in khat-mediated cell death has been further demonstrated 
in preliminary experiments using primary cells from AML patients. The experiments showed 
that khat caused cytotoxic effects in leukemic cells from 1 out of 4 patients (results not 
shown).   
The AML cell lines used in this study are characterized by various genetic aberrations 
that could explain the differences in sensitivity. In paper I we concluded that neither the 
presence of FLT3-ITDs nor the mutational status of TP53, both important prognostic 
markers, seemed to account for the different khat sensitivities exhibited by the cell lines. 
However, the presence of other genetic aberrations may influence the signaling pathways 
regulated by the Flt3 receptor and the tumour suppressor p53. For instance, MLL
translocations are found in leukemias of both myeloid and lymphoid origin and represent a 
poor prognostic factor with adverse effects on treatment response (195). A proposed 
mechanism for MLL fusion proteins involves reduced acetylation of p53 by p300, which 
would abrogate its stabilization and activation (172).  
The khat-resistant MV-4-11 cell line carries the t(4;11) translocation, the most 
common MLL translocation in acute lymphoblastic leukemia, encoding the MLL-AF4 fusion 
protein. However, the khat-sensitive MOLM-13 cell line has been shown to expresses a 
MLL-AF9 fusion mRNA, resulting from a minute chromosomal insertion, 
ins(11;9)(q23;p22p23)(196). The expression of distinct MLL fusion proteins in MV-4-11 
and MOLM-13 could indicate different effects on intracellular signaling. However, the 
presence of chimeric MLL proteins in both cell lines could also suggest other characteristics 
as more important in determining the differences in khat sensitivity (197).  
45
MV-4-11 has been shown to carry a K-RAS mutation which has been suggested to 
inhibit the function of the p53 protein (198, 199). Oncogenic K-Ras has also been shown to 
activate the PI3K/AKT pathway, which could explain the lack of Mcl-1 down-regulation in 
this cell line as compared to MOLM-13 in paper I (200). Further, oncogenic K-Ras could 
mediate increased levels of ROS and constitutive activation of p38, which acts up-stream of 
p53 (201, 202). In conclusion, the AML cell lines used in this study carry a range of genetic 
aberrations which could provide the molecular basis for the different khat sensitivites that 
were observed.  
In paper III, we observed that khat was less cytotoxic to normal PBMCs compared to 
the khat-sensitive AML cell lines, in agreement with previous results (62). Khat was shown 
to induce significant cytotoxic effects after 6 hours, and cell proliferation was observed to be 
inhibited by approximately 50% after 4 days of treatment. Despite the induction of cell death, 
the study demonstrated the presence of viable and actively proliferating cells after long-time 
exposures to khat. However, the study did not assess cytotoxic effects in the various subsets 
of the complex population of immune cells. The treatments were observed to induce different 
intracellular responses in the cell subsets, and it is reasonable to expect that the populations 
would exhibit different sensitivities to khat. 
5.2 Modes of programmed cell death 
Mitochondria are known to play a central role in induction of different types of cell death, 
and may mediate death through release of cell death agonists and by generating excess levels 
of ROS (92). When comparing ultra structural features by TEM in paper I it was evident that 
khat, in contrast to CPT, caused extensive damage to the mitochondria in MOLM-13. 
Pharmacological targeting of mitochondrial function has been suggested as a possible 
therapeutic intervention (203, 204). However, even cells in late phases of cell death, 
contained apparently intact mitochondria in addition to the damaged ones. This suggested, 
although impaired, ongoing mitochondrial ATP production which could fuel the energy-
dependent processes of apoptosis and autophagy (184). Impaired mitochondrial function may 
trigger autophagy, as it is initiated in times of nutrient deprivation and other forms of cellular 
stress (87, 88). Therefore, mitochondrial impairment could have triggered the morphological 
characteristics of autophagy that were observed in khat-treated MOLM-13 cells in paper I. 
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Autophagosome formation was observed in cells in early stages of cell death, whereas 
extensive vacuolization of the cytoplasm characterized cells in late phases (85, 184).  
In paper II, the use of Lyso Tracker® Red DND-99 demonstrated an increase in the 
level of acidic cellular organelles, further indicating activation of the autophagosomal-
lysosomal pathway in MOLM-13 (184). When pre-treating MOLM-13 with specific p38 
inhibitors, the khat-induced increase in acidic organelles was abolished. p38 acts up-stream 
of p53 and the inhibitors could therefore have hindered p53 activation (201). p53 has the 
potential to trigger autophagy, but is reported to play a dual role, with nuclear p53 inducing 
autophagy genes, whereas cytoplasmic p53 represses its activation (205). However, p38 has 
been shown to induce transcription of autophagy genes in response to elevated ROS levels, 
indicating that khat-mediated autophagy could be induced up-stream of p53 (206). In order to 
further verify the involvement of autophagy, biochemical events like dissociation of Beclin-1 
from anti-apoptotic Bcl-2 family members and degradation of the p62 protein should be 
investigated (85).  
We previously reported that khat-mediated cell death in HL-60 displayed typical 
morphological and biochemical characteristics of apoptosis, including nuclear fragmentation 
and procaspase-3 activation (62). When comparing the nuclei in cells undergoing khat-
mediated death, MOLM-13 and HL-60 were observed to display different nuclear 
morphologies (results not shown). Whereas chromatin was observed to be condensed and 
localized to the margins of the nuclei in MOLM-13, HL-60 demonstrated characteristic 
apoptotic nuclei with condensed and fragmented chromatin (62). Autophagy as a mode of 
cell death is characterized by absence of chromatin condensation, and this observation 
indicated that several death-inducing pathways could be activated in MOLM-13. Further, the 
observation of distinct nuclear morphologies indicated that khat triggered different modes of 
programmed cell death in individual AML cell lines. The morphological differences were 
further supported by Western blot analyses of khat-treated MOLM-13 cells, which 
demonstrated limited procaspase-3 activation (results not shown), contrasting with the 
analyses of HL-60.  
It has been demonstrated that the concentration of anti-cancer drugs may dictate the 
mode of cell death in experimental cell cultures. Drugs may induce necrosis when 
administered at a high dose while inducing apoptosis at lower concentrations (90, 184). It is 
therefore possible that the type of programmed cell death and the exact signaling pathway(s) 
involved could be altered by changing the concentration of khat. It has also been 
47
demonstrated that dying cells may display morphological characteristics of more than one 
type of cell death (85, 90). 
5.3 Potential molecular targets of khat and the khat amphetamines 
In paper I we focused on the Bcl-2 family of proteins, important regulators of mitochondria-
mediated cell death (94). Bcl-2 family proteins are frequently aberrantly expressed in cancer, 
and over-expression of anti-apoptotic members is shown to mediate therapeutic resistance 
and poor survival (109, 110). The level of khat-induced cell death was reduced by increased 
Bcl-2 in the rat acute myeloid leukemia IPC-81 Bcl-2 cell line. This cell clone is transfected 
to express a BCL-2 gene of human origin and has been shown to be resistant to pro-apoptotic 
stimuli (207). In agreement with previous reports, CPT-induced cell death was inhibited in 
this cell line (208, 209). Khat-mediated cell death was significantly inhibited by Bcl-2 over-
expression in the human promyelocytic NB4 cell line. However, there did not appear to be a 
correlation between khat sensitivity and the endogenous levels of Bcl-2 and Bax in the 
various AML cell lines. Furthermore, Western blot analyses of khat-treated cells 
demonstrated that the protein levels of Bcl-2 and Bax remained relatively constant. These 
observations suggested that sensitivity was dictated by other molecular characteristics and 
that khat did not target the Bcl-2/Bax proteins directly.  
However, khat was shown to mediate significant reductions in expression levels of 
the anti-apoptotic Mcl-1 protein. This Bcl-2 family protein primarily exerts its function in the 
mitochondrial OM where it binds and antagonizes pro-apoptotic Bcl-2 family members. Mcl-
1 degradation following UV irradiation has been shown to be required for mitochondrial 
cytochrome c release and subsequent activation of procaspases (120). It has been reported 
that therapeutic targeting of Bcl-2 family members and induction of apoptosis depends on 
neutralization of Mcl-1 (121). In addition to its role in mitochondria, Mcl-1 has been shown 
to antagonize receptor-mediated cell death by inhibiting truncated (t) BID. tBID is generated 
by caspase-8 mediated cleavage of BID, and the truncated protein promotes cytochrome c 
release from mitochondria (123-125). Mcl-1 has also been reported to interact with Beclin-1, 
an autophagy-promoting protein that contains a BH3 domain (101, 122). BH3-only pro-
apoptotic proteins of the Bcl-2 family promote autophagy by disrupting the binding of 
Beclin-1 to anti-apoptotic Bcl-2 proteins (210). Khat-mediated down-regulation of Mcl-1 
could therefore be involved in induction of autophagy in MOLM-13. 
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The observations in this study indicate that Mcl-1 may represent a central molecular 
target in khat-induced cell death. Mcl-1 is frequently over-expressed in cancers and has been 
shown to mediate chemoresistance (117-119). The plant-derived compound silvestrol was 
recently shown to induce early reductions in Mcl-1 levels due to translational inhibition, 
mediating subsequent mitochondrial damage (211). Other plant-derived compounds, like 
Apogossypol, have also been demonstrated to target Mcl-1 and other anti-apoptotic Bcl-2 
family members when inducing apoptosis (112, 113). 
Pre-treatment of HL-60 with the specific caspase-8 inhibitor, Z-IETD-FMK, was 
previously shown to protect against khat-induced apoptosis (62). In paper I we demonstrated 
the presence of active caspase-8 in khat-exposed cells, further supporting involvement of 
signaling via cell surface death receptors. In addition, we demonstrated a relatively rapid 
cleavage of the caspase-8 antagonist c-FLIPL to the cleavage product p43-FLIP. This 
cleavage product has been shown to be generated by activated caspase-8, whereas 
procaspase-8 cleaves FLIPL to a fragment of 22 kDa, p22-FLIP. The smaller c-FLIP fragment 
has been shown to activate NF-kB signaling, hence mediating cell survival (128). 
c-FLIP over-expression has been shown to confer resistance to receptor-mediated 
apoptosis in B-cell chronic lymphocytic leukemia, multiple carcinomas (e.g. colourectal, 
gastric, pancreatic and ovarian) and Hodgkin/Reed-Sternberg cells (129-131). Down-
regulation of c-FLIP sensitizes tumour cells to apoptosis-induction by extracellular death 
ligands (132-134). Various anti-cancer drugs including doxorubicin, actinomycin D, CHX, 
CPT, bortezomib, cisplatin and trichostatin A have been shown to reduce c-FLIP levels (129, 
135). The anti-cancer therapeutics phenoxodiol, an analogue of a soybean isoflavone, is 
believed to inhibit XIAP and c-FLIP, thereby facilitating induction of apoptosis (136, 137). 
The potential of c-FLIP as a therapeutic target has recently been reviewed (129, 212). 
c-FLIP down-regulation has been shown to occur in conjunction with ROS generation 
(213), and c-FLIP cleavage was reported to induce ROS (214). Lukandu et al. demonstrated 
that khat-mediated apoptosis in oral keratinocytes and fibroblasts involved generation of 
ROS (60). These observations could suggest that caspase-8 mediates c-FLIPL cleavage in 
MOLM-13, which then could trigger increased levels of ROS. However, whether ROS may 
trigger c-FLIP down-regulation or if reduced c-FLIP levels may cause elevated levels of 
ROS, remains to be further elucidated. Interestingly, it has been shown that treating leukemic 
cells with inhibitors of ROS elimination and complex I inhibitors, mediates increased 
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sensitivity to drug-induced apoptosis (203). An overview of the results discussed in this 
section is provided in figure 7. 
Figure 7. Overview of proteins that were affected by khat treatment and possible involved cell death pathways.  
In paper III we compared single cell signal responses in normal peripheral blood 
leukocytes to khat and the khat amphetamines: cathinone, cathine and norephedrine. 
Whereas khat was observed to induce activating protein modifications, the khat 
amphetamines attenuated phosphorylation of several signaling transducers including AKT, 
STAT6 and CREB. This suggested that the khat amphetamines could have potential as 
inhibitors of signal transduction pathways. In a recent study by Krutzik et al. primary 
splenocytes were used to evaluate inhibitors of intracellular pathways first identified in a 
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leukemic cell line. The use of heterogenous population of immune cells demonstrated 
pathway-specificity and in addition identified cell type-specific inhibitors (4).
5.4 Modulations of the p53 protein and cytotoxic effects 
We previously reported that khat activated p53 in primary oral keratinocytes and fibroblasts, 
mediating transcription of p21 and induction of cell cycle arrest (59). When exposed to a 
higher concentration of khat the oral fibroblasts and keratinocytes underwent programmed 
cell death, involving ROS and impaired mitochondrial integrity and function (60, 61). This 
indicated that p53 could be involved in khat-mediated cell death in AML cell lines, and 
regulation of the p53 protein was studied in paper II. However, we previously reported that 
AML cell lines without TP53 and mutated TP53 were sensitive to khat-induced cell death, 
suggesting involvement of a p53-independent cell death pathway. 
Based on flow cytometric analyses khat was shown to induce phosphorylation and 
acetylation of p53 in both khat-sensitive MOLM-13 cells and the khat-resistant MV-4-11 cell 
line. These PTMs are reported to mediate stabilization and accumulation of the p53 protein, 
by inhibiting Mdm2-mediated ubiquitination and degradation (149, 150). However, 
accumulation of the full length p53 isoform, p53 FL, was only seen in MOLM-13, whereas 
the levels of the truncated / p53 isoforms were reduced. A similar p53 isoform modulation 
was previously reported in AML patients receiving induction chemotherapy (192). The 
expression of various p53 isoforms represents a means of regulating the transcriptional 
activity of p53 and the cellular response to stress signals (215).  
p53 was shown to induce transcription of p21 and Mdm2, whereas levels of pro-
apoptotic Bcl-2 family proteins like Bax and Noxa remained constant. In addition to 
inducing transcription of pro-apoptotic genes, p53 is known to have direct death promoting 
functions, and p53 and Mcl-1 have been shown to have opposite effects on mitochondrial 
OM stability (163). The results in paper I and II could therefore suggest that khat destabilized 
the mitochondria through elevated p53 and down-regulation of Mcl-1 in MOLM-13. 
However, pre-incubation with pifithrin , which inhibits the transcription-independent 
activity of p53 in mitochondria (216), did not affect the level of khat-induced cell death in 
MOLM-13 (results not shown). This further suggested that khat-mediated cell death was 
independent of p53 in AML cell lines. In paper II, experiments using p53 -/- bone marrow 
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cells and MOLM-13 p53 knock-down cells demonstrated that p53 was not necessary in khat-
mediated cell death. Further, protein analyses of p63 and p73 indicated that these p53 family 
members remained unaltered (217, 218).  
The p53 protein was only induced by the death-inducing khat concentration in 
MOLM-13, and not by sub-lethal dilutions or in the khat-resistant MV-4-11 cell line. In 
paper III, the cytotoxic khat concentration induced p53 in a subset of normal peripheral blood 
leukocytes and was shown to induce cell death and reduced proliferation of PBMCs. 
Together these observations suggested that p53 could represent an indicator for sensitivity to 
khat and its cytotoxic constituents. We therefore suggested that the p53 isoform pattern and 
its post-translational modifications could be useful in evaluation of biological effects of 
extracts, and when screening for novel chemical probes and experimental therapeutics.  
5.5 Cytotoxic khat constituents 
Alkaloids have contributed the largest number of substances to the modern pharmacopeia, 
and the vinca alkaloids represent one of the main classes of compounds used as anti-cancer 
therapeutics (1). The khat alkaloid cathinone was termed a natural amphetamine due to its 
similarities with amphetamine, and various amphetamines have been shown to induce 
apoptosis in neuronal cells (219, 220). The alkaloid fraction in khat was indicated to mediate 
cytotoxic effects in an early study (25), and cathinone was shown to have a mitodepressive 
effect on dividing cells in root tips, indicating a cytotoxic potential (221). These observations 
suggested that the khat amphetamines could account for khat-mediated cell death in AML 
cell lines (63). In agreement with this, we previously observed that the khat amphetamines 
were cytotoxic to HL-60 cells, and suggested that these compounds were partly responsible 
for the cell death inducing potential of khat (62). In contrast, the khat amphetamines did not 
induce cell death in primary oral fibroblasts and keratinocytes (59). However, the results in 
paper IV in this study showed limited cytotoxic effects by the khat amphetamines in HL-60 
and MOLM-13 cells, and demonstrated that other compounds were responsible for the 
cytotoxicity of the khat extract.  
There are several possible explanations for the contradiction between our previous 
results and the findings in paper IV. The HL-60 cell line used in the previous study is no 
longer available in our laboratory, and it is possible that the new cell clone used in this thesis 
is slightly different. Cultivation of cell lines is known to represent a selection process, which 
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ultimately could result in an altered genetic expression profile of the cells. In addition, the 
previous study was performed in a different laboratory, suggesting that the experiments could 
have been performed under slightly different conditions (CO2 levels, batch of FBS etc.) that 
might have affected the results.  
When comparing the cytotoxicities of the khat extracts from 2005 and 2007 in AML 
cell lines, the extract from 2005 was observed to be most toxic (results not shown). The 
concentrations of khat amphetamines in the 2005 extract were lower than their 
concentrations in the less toxic extract from 2007 (Table 5). These observations further 
suggested that the cytotoxic potential of khat was not due to the content of khat 
amphetamines, in agreement with the findings in paper IV. However, we observed an 
increased signal with the WST-1 viability/proliferation assay in cathinone-exposed MOLM-
13 cells in paper IV. This could indicate increased levels of cellular ROS, and hence a 
cytotoxic effect, or reflect onset of cell differentiation (Herfindal, unpublished data).  
When evaluating early intracellular responses and cytotoxic potentials of khat and the 
khat amphetamines in normal peripheral blood cells in paper III, only khat was observed to 
induce stress proteins, and shown to induce cell death and reduced proliferation. Cancer cells 
are known to be more sensitive to cell death-induction compared to normal cells when 
exposed to drugs targeting deregulated pathways (222). Since the khat amphetamines were 
observed to be relatively non-toxic to AML cell lines in this study, it was not surprising that 
the normal blood cells appeared resistant. On the contrary, the compounds were shown to 
stimulate cell division, with norephedrine mediating significant increased proliferation of 
PBMCs. This observation agreed with a previous report where cathinone was demonstrated 
to stimulate B-cells (41). 
In paper IV, fractionation of the khat extract and bio-guided screening for cytotoxicity 
in HL-60 and MOLM-13 cells, led to the identification of a phenylpropanoid glycoside 
indicated to represent the major cytotoxic constituent in the extract. The molecule was 
suggested to consist of two central phenylpropanoid glycosides with five attached comaryl-
groups. Phenylpropanoid glycosides are common in plants, and known to possess biological 
activities including anti-viral, anti-microbial and anti-cancer effects. Coumarin derivatives 
have been reported to inhibit proliferation of leukemic cells and to induce apoptosis (223). 
Zimmermann and Zneden reported of a phenylpropanoid glycoside with four p-coumarol 
esters linked to the sugar moiety, shown to possess anti-cancer activity (224, 225). More than 
100 phenylpropanoid glycosides have been identified and characterized, but most plants 
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contain limited quantities of these potential therapeutics (226). However, further studies need 
to be done in order to fully identify the molecular structure of the cytotoxic khat 
component(s) described in paper IV.  
5.6 Concluding remarks 
This study has elucidated mechanisms underlying khat cytotoxicity in AML cell lines, and 
identified possible cellular and molecular targets with potential within anti-cancer 
treatments. When compared with the anti-cancer therapeutics CPT, khat was shown to 
mediate a different and specific cell death phenotype. However, the exact sequence of 
cellular and molecular events mediating cell death is still not determined. A complex 
cytotoxic plant extract is likely to activate several cellular pathways simultaneously, which 
will make it difficult to determine the pathway of cell death-execution.  
Analyses of p53 protein protein isoforms and its PTMs were suggested to represent a 
means for characterizing cytotoxicity by khat and other complex extracts. In contrast to khat, 
the natural khat amphetamines were not observed to be significantly cytotoxic to AML cell 
lines or to PBMCs, and were shown to stimultate proliferation of the latter. Bio-guided 
screening of khat fractions in AML cell lines led to the identification and partial 
characterization of the main cytotoxic component(s) in the khat extract, which was suggested 
to be a phenylpropanoid glycoside.  
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6. FUTURE PERSPECTIVES 
The cellular and molecular mechanisms underlying khat-mediated cytotoxicity should be 
further investigated. The molecular basis for resistance to khat should be determined, in 
order to elucidate the pathway(s) mediating cell death. Khat was shown to activate 
components of the receptor-mediated death pathway, and studies should assess the 
involvement of death receptors.  
Khat was shown to trigger autophagy, and its role in cell death-induction should be 
investigated. Further, the involvement of p38 in the autophagosomal-lysosomal pathway and 
khat-mediated cell death should be explored. The khat-induced modulation of p53 should be 
compared with other cytotoxic compounds, in order to evaluate whether specific p53 isoform 
patterns could indicate the underlying mechanisms. 
The effects of khat and the khat amphetamines on intracellular signaling in normal 
peripheral leukocytes should be further studied. Experiments evaluating the duration of the 
transient protein modifications should be performed, in order to elucidate activation or 
attenuation of intracellular signaling cascades. In addition, studies should evaluate whether 
the khat amphetamines could function as specific inhibitors of signaling pathways.  
 The exact structure of the main cytotoxic compound(s) in khat should be determined. 
The cytotoxic effects of this compound should be investigated in leukemic cells, in normal 
peripheral blood cells, in addition to its effects on normal cells of the oral cavity and 
gastrointestinal tract. To further evaluate the anti-cancer potential of khat constituents more 
experiments with primary AML patient samples should be carried out, and the compound(s) 
could eventually be tested in established animal models of AML. 
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